Search

Your search keyword '"Bini, Marta"' showing total 50 results
Start Over Author "Bini, Marta" Search Limiters Academic (Peer-Reviewed) Journals
50 results on '"Bini, Marta"'

1. Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?

Author

Venanzi, Francesco Maria, Bini, Marta, Nuccio, Antonio, De Toma, Alessandro, Lambertini, Matteo, Ogliari, Francesca Rita, Oresti, Sara, Viganò, Maria Grazia, Brioschi, Elena, Polignano, Maggie, Naldini, Matteo Maria, Riva, Silvia, Ferrara, Michele, Fogale, Nicola, Damiano, Giuseppe, Russo, Vincenzo, Reni, Michele, Veronesi, Giulia, Foggetti, Giorgia, Conforti, Fabio, Bulotta, Alessandra, and Ferrara, Roberto

Published
2023
Full Text
View/download PDF

2. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Author

Manglaviti, Sara, Bini, Marta, Apollonio, Giulia, Zecca, Ernesto, Galli, Giulia, Sangaletti, Sabina, Labianca, Alice, Sottotetti, Elisa, Brambilla, Marta, Occhipinti, Mario, Proto, Claudia, Prelaj, Arsela, Signorelli, Diego, De Toma, Alessandro, Viscardi, Giuseppe, Beninato, Teresa, Mazzeo, Laura, Bottiglieri, Achille, Leporati, Rita, Fotia, Giuseppe, Ganzinelli, Monica, Portararo, Paola, Garassino, Marina Chiara, de Braud, Filippo G.M., Lo Russo, Giuseppe, Torri, Valter, and Ferrara, Roberto

Published
2023
Full Text
View/download PDF

3. Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes

Author

Lebreton, Coriolan, Quesada, Stanislas, Bini, Marta, Babin, Guillaume, Rossi, Léa, Chopin, Nicolas, Croce, Sabrina, Hartog, Cécile, Renaud, Tiphaine, Gaillard, Anne-Lise, Petit, Adeline, Serre, Anne-Agathe, Trédan, Olivier, Rowinski, Elise, Cockenpot, Vincent, Treilleux, Isabelle, Rousset-Jablonski, Christine, Méeus, Pierre, Guyon, Frédéric, and Ray-Coquard, Isabelle

Published
2023
Full Text
View/download PDF

4. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

Author

Manglaviti, Sara, Brambilla, Marta, Signorelli, Diego, Ferrara, Roberto, Lo Russo, Giuseppe, Proto, Claudia, Galli, Giulia, De Toma, Alessandro, Occhipinti, Mario, Viscardi, Giuseppe, Beninato, Teresa, Zattarin, Emma, Bini, Marta, Lobefaro, Riccardo, Massa, Giacomo, Bottiglieri, Achille, Apollonio, Giulia, Sottotetti, Elisa, Di Mauro, Rosa Maria, Trevisan, Benedetta, Ganzinelli, Monica, Fabbri, Alessandra, de Braud, Filippo G.M., Garassino, Marina Chiara, and Prelaj, Arsela

Published
2022
Full Text
View/download PDF

7. Uterine serous carcinoma

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y.L., Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Nout, Remi A., Lorusso, Domenica, Vaughan, Michelle M., Bini, Marta, Takano, Masashi, Provencher, Diane, Indini, Alice, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Candido dos Reis, Francisco J., Lopez, Salvatore, Mariani, Andrea, Leitao, Mario M., Jr, Raspagliesi, Francesco, Panici, Pieluigi Benedetti, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, and Monk, Bradley J.

Published
2021
Full Text
View/download PDF

11. #269 Real-life experience of pazopanib in uterine leyomiosarcoma (U-LMS) in a tertiary oncologic center in Italy: evaluation of safety and effectiveness

Author

Mantiero, Mara, primary, Ducceschi, Monika, additional, Polignano, Maggie, additional, Bini, Marta, additional, Lopez, Salvatore, additional, Cavalli, Chiara, additional, Franza, Andrea, additional, Rota, Simone, additional, Fabbroni, Chiara, additional, Raspagliesi, Francesco, additional, Casali, Paolo Giovanni, additional, and Sanfilippo, Roberta, additional

Published
2023
Full Text
View/download PDF

12. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer

Author

Ducceschi, Monika, primary, Polignano, Maggie, additional, Bini, Marta, additional, Lopez, Salvatore, additional, Conca, Elena, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Carlo Stella, Giulia, additional, Petrella, Maria Cristina, additional, Carciotto, Rosaria, additional, Artioli, Grazia, additional, Maffeis, Valeria, additional, Sartor, Lucia, additional, Raspagliesi, Francesco, additional, and Mantiero, Mara, additional

Published
2023
Full Text
View/download PDF

14. ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases

Author

Bini, Marta, primary, Gantzer, Justine, additional, Dufresne, Armelle, additional, Vanacker, Hélène, additional, Romeo, Clémence, additional, Franceschi, Tatiana, additional, Treilleux, Isabelle, additional, Pissaloux, Daniel, additional, Tirode, Franck, additional, Blay, Jean-Yves, additional, Ray-Coquard, Isabelle, additional, and Brahmi, Mehdi, additional

Published
2023
Full Text
View/download PDF

15. A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.

Author

Mantiero, Mara, Bini, Marta, Polignano, Maggie, Porcu, Luca, Sanfilippo, Roberta, Fabbroni, Chiara, Parma, Gabriella, Lapresa, Mariateresa, Calidona, Carmelo, Silvestri, Cecilia, Franza, Andrea, Raspagliesi, Francesco, Colombo, Nicoletta, and Ducceschi, Monika

Subjects
*THERAPEUTIC use of antineoplastic agents, *LEIOMYOSARCOMA, *DRUG efficacy, *RESEARCH, *HYPERTENSION, *HEALTH facilities, *DIARRHEA, *NAUSEA, *UTERINE tumors, *RETROSPECTIVE studies, *EXPERIENCE, *VOMITING, *DESCRIPTIVE statistics, *DRUG side effects, *PATIENT safety, *OVERALL survival, *DRUG toxicity, *EVALUATION
Abstract

Simple Summary: Pazopanib is an oral drug for metastatic pretreated uterine leiomyosarcoma that received approval in 2012, but poor data have been reported on its activity in real life since the disease is very rare. Uterine leiomyosarcoma has a poor objective response rate to other agents. We assessed the effectiveness and safety of pazopanib in everyday clinical practice, showing its activity and tolerability in patients. Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice. Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey. Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred. Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Endometrial carcinosarcoma

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, Mccormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, Mccormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

Published
2023

17. Endometrial carcinosarcoma

Author

Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, and Monk, Bradley J

Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

Published
2023

18. Endometrial carcinosarcoma

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Concin, Nicole, additional, Ngoi, Natalie Yan Li, additional, Morice, Philippe, additional, Caruso, Giuseppe, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Coleman, Robert, additional, Vaughan, Michelle M, additional, Takano, Masashi, additional, Provencher, Diane Michele, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Póka, Robert, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Candido dos Reis, Francisco Jose, additional, Ramirez, Pedro T, additional, Mariani, Andrea, additional, Leitao, Mario, additional, Makker, Vicky, additional, Abu-Rustum, Nadeem R, additional, Vergote, Ignace, additional, Zannoni, Gianfranco, additional, Tan, David, additional, McCormack, Mary, additional, Paolini, Biagio, additional, Bini, Marta, additional, Raspagliesi, Francesco, additional, Benedetti Panici, Pierluigi, additional, Di Donato, Violante, additional, Muzii, Ludovico, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Scambia, Giovanni, additional, and Monk, Bradley J, additional

Published
2022
Full Text
View/download PDF

20. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

Author

Di Cosimo, Serena, primary, La Rocca, Eliana, additional, Ljevar, Silva, additional, De Santis, Maria Carmen, additional, Bini, Marta, additional, Cappelletti, Vera, additional, Valenti, Marta, additional, Baili, Paolo, additional, de Braud, Filippo G., additional, Folli, Secondo, additional, Scaperrotta, Gianfranco, additional, Volpi, Chiara, additional, Vingiani, Andrea, additional, Vernieri, Claudio, additional, Verderio, Paolo, additional, Miceli, Rosalba, additional, and Pruneri, Giancarlo, additional

Published
2022
Full Text
View/download PDF

21. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

Author

Bini, Marta, primary, Quesada, Stanislas, additional, Meeus, Pierre, additional, Rodrigues, Manuel, additional, Leblanc, Eric, additional, Floquet, Anne, additional, Pautier, Patricia, additional, Marchal, Frédéric, additional, Provansal, Magali, additional, Campion, Loïc, additional, Causeret, Sylvain, additional, Gourgou, Sophie, additional, Ray-Coquard, Isabelle, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, De La Motte Rouge, Thibault, additional, Barranger, Emmanuel, additional, Savoye, Aude Marie, additional, Guillemet, Cécile, additional, Gladieff, Laurence, additional, Demarchi, Martin, additional, Rouzier, Roman, additional, Courtinard, C, additional, Romeo, Clémence, additional, and Joly, Florence, additional

Published
2022
Full Text
View/download PDF

22. Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study

Author

Niger, Monica, primary, Nichetti, Federico, additional, Casadei‐Gardini, Andrea, additional, Rizzato, Mario Domenico, additional, Pircher, Chiara, additional, Bini, Marta, additional, Franza, Andrea, additional, Rimini, Margherita, additional, Burgio, Valentina, additional, Sposetti, Caterina, additional, Fornaro, Lorenzo, additional, Rapposelli, Ilario Giovanni, additional, D'Amico, Francesco Enrico, additional, Aprile, Giuseppe, additional, Vivaldi, Caterina, additional, Frassineti, Giovanni Luca, additional, Milione, Massimo, additional, Leoncini, Giuseppe, additional, Cappetta, Alessandro, additional, Vasile, Enrico, additional, Fassan, Matteo, additional, Morano, Federica, additional, Perrone, Federica, additional, Tamborini, Elena, additional, Pruneri, Giancarlo, additional, Lonardi, Sara, additional, Mazzaferro, Vincenzo, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, and de Braud, Filippo, additional

Published
2022
Full Text
View/download PDF

23. Abstract 1269: Negative ultra-selection of patients with RAS/BRAF wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based therapy: The PRESSING2 study

Author

Randon, Giovanni, primary, Maddalena, Giulia, additional, Germani, Marco Maria, additional, Pagani, Filippo, additional, Bergamo, Francesca, additional, Giordano, Mirella, additional, Pircher, Chiara, additional, Sposetti, Caterina, additional, Zambelli, Luca, additional, Corti, Francesca, additional, Bini, Marta, additional, Rametta, Alessandro, additional, Spagnoletti, Andrea, additional, Montagna, Aldo, additional, Fassan, Matteo, additional, Boccaccino, Alessandra, additional, Vetere, Guglielmo, additional, Damian, Silvia, additional, Milione, Massimo, additional, de Braud, Filippo, additional, Cremolini, Chiara, additional, Lonardi, Sara, additional, and Pietrantonio, Filippo, additional

Published
2022
Full Text
View/download PDF

24. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

Author

Niger, Monica, primary, Nichetti, Federico, additional, Casadei‐Gardini, Andrea, additional, Morano, Federica, additional, Pircher, Chiara, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Canale, Matteo, additional, Lipka, Daniel B., additional, Vingiani, Andrea, additional, Agnelli, Luca, additional, Dobberkau, Anna, additional, Hüllein, Jennifer, additional, Korell, Felix, additional, Heilig, Christoph E., additional, Pusceddu, Sara, additional, Corti, Francesca, additional, Droz, Michele, additional, Ulivi, Paola, additional, Prisciandaro, Michele, additional, Antista, Maria, additional, Bini, Marta, additional, Cattaneo, Laura, additional, Milione, Massimo, additional, Glimm, Hanno, additional, Köhler, Bruno C., additional, Pruneri, Giancarlo, additional, Hübschmann, Daniel, additional, Fröhling, Stefan, additional, Mazzaferro, Vincenzo, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, and de Braud, Filippo, additional

Published
2022
Full Text
View/download PDF

27. Clear cell carcinoma of the endometrium

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y L, Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco J, Mariani, Andrea, Leitao, Mario M, Makker, Viky, Rustum, Nadeem Abu, Vergote, Ignace, Zannoni, Gian Franco, Tan, David S P, Mccormack, Mary, Bini, Marta, Lopez, Salvatore, Raspagliesi, Francesco, Panici, Pierluigi Benedetti, di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, Monk, Bradley J, Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y L, Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco J, Mariani, Andrea, Leitao, Mario M, Makker, Viky, Rustum, Nadeem Abu, Vergote, Ignace, Zannoni, Gian Franco, Tan, David S P, Mccormack, Mary, Bini, Marta, Lopez, Salvatore, Raspagliesi, Francesco, Panici, Pierluigi Benedetti, di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, Monk, Bradley J, Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma. (C) 2022 Elsevier Inc. All rights reserved.

Published
2022

29. Clear cell carcinoma of the endometrium

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Concin, Nicole, additional, Ngoi, Natalie Y.L., additional, Morice, Philippe, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Coleman, Robert, additional, Vaughan, Michelle M., additional, Takano, Masashi, additional, Provencher, Diane, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Póka, Robert, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Candido dos Reis, Francisco J., additional, Mariani, Andrea, additional, Leitao, Mario M., additional, Makker, Viky, additional, Rustum, Nadeem Abu, additional, Vergote, Ignace, additional, Zannoni, Gian Franco, additional, Tan, David S.P., additional, McCormack, Mary, additional, Bini, Marta, additional, Lopez, Salvatore, additional, Raspagliesi, Francesco, additional, Panici, Pierluigi Benedetti, additional, di Donato, Violante, additional, Muzii, Ludovico, additional, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Pignata, Sandro, additional, and Monk, Bradley J., additional

Published
2022
Full Text
View/download PDF

30. Blood Bacterial DNA Load and Profiling Differ in Colorectal Cancer Patients Compared to Tumor-Free Controls

Author

Mutignani, Massimiliano, primary, Penagini, Roberto, additional, Gargari, Giorgio, additional, Guglielmetti, Simone, additional, Cintolo, Marcello, additional, Airoldi, Aldo, additional, Leone, Pierfrancesco, additional, Carnevali, Pietro, additional, Ciafardini, Clorinda, additional, Petrocelli, Giulio, additional, Mascaretti, Federica, additional, Oreggia, Barbara, additional, Dioscoridi, Lorenzo, additional, Cavalcoli, Federica, additional, Primignani, Massimo, additional, Pugliese, Francesco, additional, Bertuccio, Paola, additional, Soru, Pietro, additional, Magistro, Carmelo, additional, Ferrari, Giovanni, additional, Speciani, Michela C., additional, Bonato, Giulia, additional, Bini, Marta, additional, Cantù, Paolo, additional, Caprioli, Flavio, additional, Vangeli, Marcello, additional, Forti, Edoardo, additional, Mazza, Stefano, additional, Tosetti, Giulia, additional, Bonzi, Rossella, additional, Vecchi, Maurizio, additional, La Vecchia, Carlo, additional, and Rossi, Marta, additional

Published
2021
Full Text
View/download PDF

32. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma

Author

Di Guardo, Lorenza, primary, Randon, Giovanni, additional, Corti, Francesca, additional, Vallacchi, Viviana, additional, Raimondi, Alessandra, additional, Fucà, Giovanni, additional, Bini, Marta, additional, Maurichi, Andrea, additional, Patuzzo, Roberto, additional, Gallino, Gianfrancesco, additional, Mattavelli, Ilaria, additional, Ruggeri, Roberta, additional, Angi, Martina, additional, Cossa, Mara, additional, Valeri, Barbara, additional, Cimminiello, Carolina, additional, Santinami, Mario, additional, Rivoltini, Licia, additional, Braud, Filippo, additional, Rodolfo, Monica, additional, and Vecchio, Michele Del, additional

Published
2021
Full Text
View/download PDF

34. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer

Author

Bogani, Giorgio, Chiappa, Valentina, Bini, Marta, Ronzulli, Dominique, Indini, Alice, Conca, Elena, and Raspagliesi, Francesco

Abstract

Purpose: Advanced/recurrent cervical cancer has limited therapeutic options, with a median progression-free survival after the failure of systemic treatments ranging between 3.5 and 4.5 months. Here, we reported our preliminary experience in the use of BYL719 (alpelisib) in advanced/recurrent cervical cancer after failure of at least 2 lines of treatment. The Istituto Nazionale dei Tumori di Milano approved this investigation.Methods: From April 2020 to September 2020, 17 consecutive patients with recurrent cervical cancer had Next Generation Sequencing (NGS). Of these, six patients harboring the PIK3CA mutation were included in the study. All patients had been treated with at least 2 previous lines of systemic treatment: 3 patients received >2 prior lines of treatment in the recurrent or metastatic setting; 60% had received prior bevacizumab in combination with chemotherapy. All patients started alpelisib at the daily dosage of 300 mg.Results: Investigator-assessed confirmed objective response rate (ORR) was 33%. The disease control rate (DCR) was 100%. According to RECIST 1.1, two patients had a partial response (PR), and four patients had stable disease (SD). No complete response was observed. The mean duration of response (DOR) was 11.5 (SD 3.75) months; five patients had PR lasting for >9 months. One patient stopped the treatment at 0.82 months due to the onset of a grade 2 adverse event (AE) (skin rash). Grade 3 treatment-related AEs included: lymphoedema (n = 1, 17%) and rash (n = 1, 17%). No treatment-related grade 4-5 AEs occurred.Conclusions: Our preliminary data highlighted a high level of efficacy in this setting of patients. Further trials are needed to assess the safety and effectiveness of alpelisib in PIK3CA-mutated recurrent/advanced cervical cancer.

Published
2023
Full Text
View/download PDF

35. Blood bacterial DNA, intestinal adenoma and colorectal cancer

Author

Mutignani, Massimiliano, primary, Penagini, Roberto, additional, Gargari, Giorgio, additional, Guglielmetti, Simone, additional, Cintolo, Marcello, additional, Airoldi, Aldo, additional, Leone, Pierfrancesco, additional, Carnevali, Pietro, additional, Ciafardini, Clorinda, additional, Petrocelli, Giulio, additional, Mascaretti, Federica, additional, Oreggia, Barbara, additional, Dioscoridi, Lorenzo, additional, Cavalcoli, Federica, additional, Primignani, Massimo, additional, Pugliese, Francesco, additional, Bertuccio, Paola, additional, Soru, Pietro, additional, Magistro, Carmelo, additional, Ferrari, Giovanni, additional, Speciani, Michela, additional, Bonato, Giulia, additional, Bini, Marta, additional, Cantù, Paolo, additional, Caprioli, Flavio, additional, Vangeli, Marcello, additional, Forti, Edoardo, additional, Mazza, Stefano, additional, Tosetti, Giulia, additional, Bonzi, Rossella, additional, Vecchi, Maurizio, additional, Vecchia, Carlo La, additional, and Rossi, Marta, additional

Published
2021
Full Text
View/download PDF

36. Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

Author

Ferrara, Roberto, primary, Jachetti, Elena, additional, Calareso, Giuseppina, additional, Brambilla, Marta, additional, Lo Russo, Giuseppe, additional, Proto, Claudia, additional, Prelaj, Arsela, additional, Signorelli, Diego, additional, Galli, Giulia, additional, De Toma, Alessandro, additional, Occhipinti, Mario, additional, Manglaviti, Sara, additional, Labianca, Alice, additional, Ganzinelli, Monica, additional, Spanò, Sestina Maria, additional, Molino, Giuliano, additional, Martinetti, Antonia, additional, Greco, Francesca Gabriella, additional, Bini, Marta, additional, Beninato, Teresa, additional, de Braud, Filippo, additional, Colombo, Mario Paolo, additional, Garassino, Marina Chiara, additional, and Sangaletti, Sabrina, additional

Published
2021
Full Text
View/download PDF

37. Abstract PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy

Author

Prelaj, Arsela, primary, Boeri, Mattia, additional, Robuschi, Alessandro, additional, Proto, Claudia, additional, Russo, Giuseppe Lo, additional, Ferrara, Roberto, additional, Galli, Giulia, additional, De Toma, Alessandro, additional, Brambilla, Marta, additional, Occhipinti, Mario, additional, Manglaviti, Sara, additional, Labianca, Alice, additional, Beninato, Teresa, additional, Bini, Marta, additional, Mensah, Mavis, additional, Ganzinelli, Monica, additional, Zilembo, Nicoletta, additional, de Braud, Filippo, additional, Sozzi, Gabriella, additional, Restelli, Marcello, additional, Pedrocchi, Alessandra, additional, Garassino, Marina Chiara, additional, and Trovo, Francesco, additional

Published
2021
Full Text
View/download PDF

38. COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study

Author

Nichetti, Federico, primary, Bini, Marta, additional, Ambrosini, Margherita, additional, Ottini, Arianna, additional, Rametta, Alessandro, additional, Leporati, Rita, additional, Polastri, Daniela, additional, Pircher, Chiara, additional, Dotti, Katia, additional, Ferrari, Laura, additional, and de Braud, Filippo, additional

Published
2020
Full Text
View/download PDF

39. Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.

Author

Corti, Francesca, primary, Randon, Giovanni, additional, Bini, Marta, additional, Raimondi, Alessandra, additional, Manglaviti, Sara, additional, Zattarin, Emma, additional, Bisogno, Ilaria, additional, Vetrano, Irene, additional, Cimminiello, Carolina, additional, De Braud, Filippo G., additional, Del Vecchio, Michele, additional, and Di Guardo, Lorenza, additional

Published
2020
Full Text
View/download PDF

40. Combined use of albumin and neutrophil-to-lymphocyte ratio as new prognostic and predictive factor in patients with poorly differentiated neuroendocrine carcinomas.

Author

Colombo, Elena, primary, Manca, Paolo, additional, Bini, Marta, additional, Bottiglieri, Achille, additional, Massa, Giacomo, additional, Prinzi, Natalie, additional, Torchio, Martina, additional, Niger, Monica, additional, Corti, Francesca, additional, Prisciandaro, Michele, additional, Zattarin, Emma, additional, Proto, Claudia, additional, Garassino, Marina Chiara, additional, Milione, Massimo, additional, Cattaneo, Laura, additional, Di Bartolomeo, Maria, additional, Platania, Marco, additional, De Braud, Filippo G., additional, Lo Russo, Giuseppe, additional, and Pusceddu, Sara, additional

Published
2020
Full Text
View/download PDF

42. Update on Management of Caustic and Foreign Body Ingestion in Children

Author

Betalli, Pietro, primary, Rossi, Alfredo, additional, Bini, Marta, additional, Bacis, Giuseppe, additional, Borrelli, Osvaldo, additional, Cutrone, Cesare, additional, Dall'Oglio, Luigi, additional, d'Angelis, Gian Luigi, additional, Falchetti, Diego, additional, Farina, Maria Luisa, additional, Gamba, PierGiorgio, additional, Gandullia, Paolo, additional, Lombardi, Giuliano, additional, Torroni, Fillippo, additional, Romano, Claudio, additional, and De Angelis, Paola, additional

Published
2009
Full Text
View/download PDF

43. Endoscopic Treatment of Anastomotic Biliary Stenosis in Patients with Orthotopic Liver Transplantation

Author

Rossi, A, Grosso, C, Zanasi, G, Gambitta, P, Bini, M, De Carlis, L, Arcidiacono, R, Rossi, Alfredo, Grosso, Claudio, Zanasi, Giulio, Gambitta, Pietro, Bini, Marta, De Carlis, Luciano, Arcidiacono, Raffaele, Rossi, A, Grosso, C, Zanasi, G, Gambitta, P, Bini, M, De Carlis, L, Arcidiacono, R, Rossi, Alfredo, Grosso, Claudio, Zanasi, Giulio, Gambitta, Pietro, Bini, Marta, De Carlis, Luciano, and Arcidiacono, Raffaele

Abstract

The choledocho-choledochostomy stricture is one of the most frequent complications occurring after liver transplantation. Today endoscopic retrograde cholangiopancreatography may be considered one of the most common methodologic approaches for the diagnosis; at the same time it provides an effective treatment of the stenosis, avoiding more invasive surgery. Biliary flow through a strictured anastomosis definitely improves after endoscopic stenting which, in most cases, resolves the biliary obstruction syndrome; moreover, the stent could allow restoration of the anatomical and functional integrity of the common bile duct. We have successfully treated eight liver transplanted patients with biliary anastomotic stenosis by endoscopic stenting of the common bile duct or by balloon dilation (one patient). The stents were replaced every 3 to 4 months and then removed after 1 year of followup. We observed one patient with acute cholangitis due to the clogging of the prosthetic device. © 1995, Harwood Academic Publishers GmbH Printed in Singapore

Published
1995

46. Nanodispersions of TiO 2 in Water for Removing Acrylic Films Used in Conservation.

Author

Giuntoli, Giulia, Bini, Marta, Ciuffi, Benedetta, Salvadori, Barbara, Baldi, Giovanni, and Rosi, Luca

Subjects
*TITANIUM dioxide, *NANOPARTICLE size, *POLYWATER, *POLYMER degradation, *IMAGE analysis
Abstract

The influence of a nanodispersion of TiO2 in water (nanoparticle size: 40 nm, polydispersity index: 0.25), brushed on a Paraloid film and subjected to UV–Vis irradiation was evaluated. The TiO2 nanodispersions showed a tendency to reduce the molecular weight of Paraloid due to its photocatalytic properties. FTIR and GPC analyses and SEM images suggested the degradation of the polymer, while chromatic variations of the films were scarcely detected. This study is very remarkable in the perspective of using this material for the removal of polymeric films used in conservation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Endoscopic Treatment of Anastomotic Biliary Stenosis in Patients With Orthotopic Liver Transplantation

Author

Rossi, Alfredo, Grosso, Claudio, Zanasi, Giulio, Gambitta, Pietro, Bini, Marta, de Carlis, Luciano, and Arcidiacono, Raffaele

Abstract

The choledocho-choledochostomy stricture is one of the most frequent complications occurring after liver transplantation. Today endoscopic retrograde cholangiopancreatography may be considered one of the most common methodologic approaches for the diagnosis; at the same time it provides an effective treatment of the stenosis, avoiding more invasive surgery. Biliary flow through a strictured anastomosis definitely improves after endoscopic stenting which, in most cases, resolves the biliary obstruction syndrome; moreover, the stent could allow restoration of the anatomical and functional integrity of the common bile duct. We have successfully treated eight liver transplanted patients with biliary anastomotic stenosis by endoscopic stenting of the common bile duct or by balloon dilation (one patient). The stents were replaced every 3 to 4 months and then removed after 1 year of follow-up. We observed one patient with acute cholangitis due to the clogging of the prosthetic device.

Published
1996
Full Text
View/download PDF

48. A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.

Author

Mantiero M, Bini M, Polignano M, Porcu L, Sanfilippo R, Fabbroni C, Parma G, Lapresa M, Calidona C, Silvestri C, Franza A, Raspagliesi F, Colombo N, and Ducceschi M

Abstract

Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice., Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey., Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred., Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.

Published
2023
Full Text
View/download PDF

49. [Treatments for rare ovarian tumors: What's new?]

Author

Lebreton C, Quesada S, Bini M, Babin G, Rossi L, Chopin N, Croce S, Hartog C, Renaud T, Gaillard AL, Petit A, Serre AA, Trédan O, Rowinski E, Cockenpot V, Treilleux I, Rousset-Jablonski C, Méeus P, Guyon F, and Ray-Coquard I

Subjects
Female, Humans, Precision Medicine, Incidence, Ovarian Neoplasms therapy, Ovarian Neoplasms pathology
Abstract

Even if each rare ovarian tumor (ROT) has a low incidence, the sum of all these entities represents almost the half of all ovarian neoplasms. Thus, development of dedicated clinical trial emerged as a prerequisite to improve their managements. Owing to the spreading of dedicated institutional networks and (supra)national collaborations, the number of clinical trials has increased the past few years, with different types of trials; while some focused on specific molecular features, others assessed innovative molecules. Furthermore, relevant randomized clinical trials were designed as a mean to position new treatment options. Currently, innovative molecular-driven trials, based on master protocol trials are emerging and may shed light towards the improvement of personalized medicine regarding ROT., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

50. Endometrial carcinosarcoma.

Author

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher DM, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Ramirez PT, Mariani A, Leitao M, Makker V, Abu-Rustum NR, Vergote I, Zannoni G, Tan D, McCormack M, Paolini B, Bini M, Raspagliesi F, Benedetti Panici P, Di Donato V, Muzii L, Colombo N, Pignata S, Scambia G, and Monk BJ

Subjects
Female, Humans, Neoplasm Recurrence, Local, Carboplatin therapeutic use, Combined Modality Therapy, Endometrial Neoplasms therapy, Endometrial Neoplasms pathology, Carcinosarcoma therapy, Carcinosarcoma drug therapy, Uterine Neoplasms pathology
Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma., Competing Interests: Competing interests: GB: Novartis AG Pharma (C/A, H), Italian Ministry of Health (RG); NC: AstraZeneca (C/A, SH), Seattle Genetics (C/A, SH), MSD (SAB), Mersana (C/A, SH), eTheRNA immunotherapies NV (C/A, SH), Roche (travel expenses), Genmab (travel expenses), Amgen (travel expenses). IR-C: honoraria from AstraZeneca, Clovis, GSK/Tesaro, and PharmaMar; consulting/advisory board fees from AstraZeneca, Roche, Clovis, GSK/Tesaro, Genmab, PharmaMar, MSD, Mersana, Deciphera, OncXea, Esai, BMS, Novartis, and Pfizer; research funding from MSD; travel expenses from AstraZeneca, GSK, and Roche. YS: AstraZeneca (CA), GSK (CA). PW: Amgen (SH, RF, SAB), AstraZeneca (SH, RF, H, SAB), Clovis (SH, RF, SAB), Eisai (SH, SAB), GSK (SH, SAB), Lilly (SH, SAB), MSD (SH, RF, SAB), Novartis (SH, RF, SAB), Pfizer (SH, RF, SAB), Roche (SH, RF, H, SAB), TEVA (SH, SAB). NYLN: AstraZeneca (SH), Janssen (SH). KT: AstraZeneca (SH), Chugai (SH, RF), Eisai (SH), MSD (SH), Mochida (SH), Takeda (SH). TE: Takeda (SH), Astra Zeneca (SH), Eisai (SH), Chugai Pharma (SH, RF), MSD (SH), Mochida (SH). DL: AstraZeneca (H, CA), Clovis (H, CA, RF), GSK/Tesaro (H, CA), Roche (CA), Genmab (CA), PharmaMar (CA, RF), MSD (CA, RF), Esai (CA), Merck Serono (CA), Novartis (CA), and PharmaMar (H); consulting/advisory board fees from AstraZeneca, Roche, Clovis, GSK/Tesaro. DMP: AstraZeneca (CA, SH, SAB), GSK (CA, SH, SAB). NRA-R: NIH/NCI Cancer Center support grant P30 CA008748 (F). HD: Roche (CA, SH, SAB), Pfizer (CA, SH, SAB), AstraZeneca (SH, SAB), Lily (SAB), GSK (SAB), Novartis (SH), Pharmamar (SH); BJM: AstraZeneca (SH, SAB), GSK (SH, SAB), Incyte (SAB), Merck (SH, SAB), Roche/Genentech (SH, SAB), Eisai (SAB), GOG-Foundation (E), US Oncology (E)., (© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results